Clinical Trial Update: PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial evaluating the combination of amivantamab and tepotinib for MET-altered non-small cell lung cancer is currently active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RYBREVANT (amivantamab-vmjw)
• Tepmetko (tepotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING